Drug Trial Radar · NCT01330030
Selegiline Patch for Treatment of Nicotine Dependence
Last checked: Nov 20, 2026Latest source record: Aug 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Jul 2005
Primary completion
Aug 2008
Study completion Jul 2011
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Apr 6, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.
Conditions
- Tobacco Use Disorder
Interventions
SelegilineDrug
6mg/24 hrs for 8 weeks
matching placeboOther
placebo/24hrs for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Expired-air Carbon Monoxide Confirmed Smoking AbstinenceTime frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University School of Medicine
Stanford, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.